Seminars in Nephrology
Volume 27, Issue 6 , Pages 609-620 , November 2007

Metabolomics as an Extension of Proteomic Analysis: Study of Acute Kidney Injury

  • Didier Portilla, MD

      Affiliations

    • Department of Nephrology, University of Arkansas for Medical Sciences, Little Rock, AK.
    • Corresponding Author InformationAddress reprint requests to Dr. Didier Portilla, Department of Nephrology, University of Arkansas for Medical Sciences, 4301 W. Markham St, Little Rock, AK 72205.
    • ,
  • Laura Schnackenberg, PhD

      Affiliations

    • Division of Systems Toxicology, National Center for Toxicological Research, Jefferson, AR.
    • ,
  • Richard D. Beger, PhD

      Affiliations

    • Division of Systems Toxicology, National Center for Toxicological Research, Jefferson, AR.

References 

  1. Vaidya VS, Bonventre JV. Mechanistic biomarkers for cytotoxic acute kidney injury. Expert Opin Drug Metab Toxicol. 2006;2:697–713
  2. Fiehn O. Metabolomics—the link between genotypes and phenotypes. Plant Mol Biol. 2002;48:155–171
  3. Nicholson JK, Lindon JC, Holmes E. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29:1181–1189
  4. Raamsdonk LM, Teusink B, Broadhurst D, Zhang N, Hayes A, Walsh MC, et al. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat Biotechnol. 2001;19:45–50
  5. Robertson DG, Reily MD, Sigler RE, Wells DF, Paterson DA, Braden TK. Metabonomics: evaluation of nuclear magnetic resonance (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants. Toxicol Sci. 2000;57:326–337
  6. Williams RE, Jacobsen M, Lock EA. 1H NMR pattern recognition and 31P NMR studies with D-serine in rat urine and kidney, time- and dose-related metabolic effects. Chem Res Toxicol. 2003;16:1207–1216
  7. Lenz EM, Bright J, Knight R, Westwood FR, Davies D, Major H, et al. Metabonomics with 1H-NMR spectroscopy and liquid chromatography-mass spectrometry applied to the investigation of metabolic changes caused by gentamicin-induced nephrotoxicity in the rat. Biomarkers. 2005;10:173–187
  8. Serkova N, Fuller TF, Klawitter J, Freise CE, Niemann CU. H-NMR based metabolic signatures of mild and severe ischemia/reperfusion injury in rat kidney transplants. Kidney Int. 2005;67:1142–1151
  9. Portilla D, Li S, Nagothu K, Megyesi J, Schnackenberg L, Safirstein RL, et al. Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int. 2006;69:2194–2204
  10. Schnackenberg LK, Dragan YP, Reily MD, Robertson DG, Beger RD. Evaluation of NMR spectral data of urine in conjunction with measured clinical chemistry and histopathology parameters to assess the effects of liver and kidney toxicants. Metabolomics. 2007;3:87–100
  11. Coen M, Lenz EM, Nicholson JK, Wilson ID, Pognan F, Lindon JC. An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR spectroscopy. Chem Res Toxicol. 2003;16:295–303
  12. Schnackenberg L, Beger RD, Dragan Y. NMR-based metabonomic evaluation of livers from rats chronically treated with tamoxifen, mestranol, and phenobarbital. Metabonomics. 2005;1:87–94
  13. Waters NJ, Waterfield CJ, Farrant RD, Holmes E, Nicholson JK. Integrated metabonomic analysis of bromobenzene-induced hepatotoxicity: novel induction of 5-oxoprolinosis. J Proteome Res. 2006;5:1448–1459
  14. Serkova N, Fuller TF, Klawitter J, Freise CE, Niemann CU. H-NMR-based metabolic signatures of mild and severe ischemia/reperfusion injury in rat kidney transplants. Kidney Int. 2005;67:1142–1151
  15. Odunsi K, Wollman RM, Ambrosone CB, Hutson A, McCann SE, Tammela J, et al. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer. 2005;113:782–788
  16. Beger RD, Schnackenberg LK, Li D, Dragan Y. Metabonomic models of human pancreatic cancer using 1D proton NMR spectra of lipids in plasma. Metabolomics. 2006;2:125–134
  17. Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, Bethel HWL, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med. 2002;8:1439–1445
  18. Mayr M, Chung YL, Mayr U, Yin X, Ly L, Troy H, et al. Proteomic and metabolomic analyses of atherosclerotic vessels from apolipoprotein E-deficient mice reveal alterations in inflammation, oxidative stress, and energy metabolism. Arterioscler Thromb Vasc Biol. 2005;25:2135–2142
  19. Naziroglu M, Karaoglu A, Aksoy AO. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology. 2004;195:221–230
  20. Price PM, Safirstein RL, Megyesi J. Protection of renal cells from cisplatin toxicity by cell cycle inhibitors. Am J Physiol. 2004;286:F378–F384
  21. Atasoyu EM, Yildiz S, Bilgi O, Cermik H, Evrenkaya R, Aktas S, et al. Investigation of the role of hyperbaric oxygen therapy in cisplatin-induced nephrotoxicity in rats. Arch Toxicol. 2005;79:289–293
  22. Santos NA, Catao CS, Martins NM, Curti C, Bianchi ML, Santos AC. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol. 2007;81:495–504
  23. Delaney J, Hodson MP, Thakkar H, Connor SC, Sweatman BC, Kenny SP, et al. Tryptophan-NAD+ pathway metabolites as putative biomarkers and predictors of peroxisome proliferation. Arch Toxicol. 2005;79:208–223
  24. Li S, Wu P, Yarlagadda P, Vadjunec NM, Proia AD, Harris RA, et al. PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am J Physiol. 2004;286:F572–F580
  25. Chinetti-Gbaguidi G, Fruchart JC, Staels B. Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy. Curr Opin Pharmacol. 2005;5:177–183
  26. Lenz EM, Bright J, Knight R, Wilson ID, Major H. A metabonomic investigation of the biochemical effects of mercuric chloride in the rat using 1H NMR and HPLC-TOF/MS: time dependent changes in the urinary profile of endogenous metabolites as a result of nephrotoxicity. Analyst. 2004;129:535–541
  27. Fleck C, Schwertfeger M, Taylor PM. Regulation of renal amino acid (AA) transport by hormones, drugs and xenobiotics—a review. Amino Acids. 2003;24:347–374
  28. Fleck C, Kretzschel I, Sperschneider T, Appenroth D. Renal amino acid transport in immature and adult rats during chromate and cisplatinum-induced nephrotoxicity. Amino Acids. 2001;20:201–215
  29. Takamoto K, Kawada M, Usui T, Ishizuka M, Ikeda D. Aminoglycoside antibiotics reduce glucose reabsorption in kidney through down-regulation of SGLT1. Biochem Biophys Res Commun. 2003;308:866–871
  30. Goldstein RS, Mayor GH, Rosenbaum RW, Hook JB, Santiago JV, Bond JT. Glucose intolerance following cis-platinum treatment in rats. Toxicology. 1982;24:273–280
  31. Goldstein RS, Mayor GH, Gingerich RL, Hook JB, Rosenbaum RW, Bond JT. The effects of cisplatin and other divalent platinum compounds on glucose metabolism and pancreatic endocrine function. Toxicol Appl Pharmacol. 1983;69:432–441
  32. Jia D, Otsuki M. Bezafibrate, a peroxisome proliferator-activated receptor (PPAR)-alpha activator, prevents pancreatic degeneration in obese and diabetic rats. Pancreas. 2003;26:286–291
  33. Koh EH, Kim MS, Park JY, Kim HS, Youn JY, Park HS, et al. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. Diabetes. 2003;52:2331–2337
  34. Bihan H, Rouault C, Reach G, Poitout V, Staels B, Guerre-Millo M. Pancreatic islet response to hyperglycemia is dependent on peroxisome proliferator-activated receptor alpha (PPARalpha). FEBS Lett. 2005;579:2284–2288
  35. Nagothu KK, Bhatt R, Kaushal GP, Portilla D. Fibrate prevents cisplatin-induced proximal tubule cell death. Kidney Int. 2005;68:2680–2693
  36. Abdel-Gayoum AA, El-Jenjan KB, Ghwarsha KA. Hyperlipidaemia in cisplatin-induced nephrotic rats. Hum Exp Toxicol. 1999;18:454–459
  37. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J, et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase (A potential mechanism for the hypolipidemic action of fibrates). J Clin Invest. 1995;95:705–712
  38. van Dijk KW, Rensen PC, Voshol PJ, Havekes LM. The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?. Curr Opin Lipidol. 2004;15:239–246
  39. Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, Gonzalez FJ, et al. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem. 1997;272:27307–27312
  40. Schnackenberg LK, Jones RC, Thyparambil S, Taylor JT, Han T, Tong W, et al. An integrated study of acute effects of valproic acid in the liver using metabonomics, proteomics, and transcriptomics platforms. OMICS. 2006;10:1–14
  41. Edmonson RD, Vondriska TM, Biederman KJ, Zhang J, Jones RC, Zheng Y, et al. Protein kinase C epsilon signaling complexes include metabolism- and transcription/translation-related proteins: complimentary separation techniques with LC/MS/MS. Mol Cell Proteomics. 2002;1:421–433
  42. Gambus A, Jones RC, Sanchez-Diaz A, Kanemaki M, van Deursen F, Edmonson RD, et al. GINS-dependent replisome progression complex controls the advance of eukaryotic DNA replication forks. Nat Cell Biol. 2006;8:358–366

 Supported by a VA Merit Award Grant and National Institutes of Health/National Institute for Diabetes and Digestive Kidney Diseases (RO1-DK075976 to D.P.).The views presented in this article do not necessarily reflect those of the US Food and Drug Administration.

PII: S0270-9295(07)00125-8

doi: 10.1016/j.semnephrol.2007.09.006

Seminars in Nephrology
Volume 27, Issue 6 , Pages 609-620 , November 2007

Article Tools

* Image Usage & Resolution